{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Qu S"],"pubmed_abstract":["<h4>Purpose</h4>To compare the efficacy and safety of the combination of transcatheter arterial chemoembolization (TACE), Lenvatinib, and programmed cell death protein-1 (PD-1) inhibitors (combination group) with TACE (TACE group) in the treatment of patients with unresectable hepatocellular carcinoma (uHCC).<h4>Methods</h4>We consecutively enrolled 110 patients with uHCC in this prospective cohort study, with 56 patients receiving combination treatment and 54 patients receiving TACE from November 2017 to September 2020. The differences in tumor response, survival benefit, and adverse events (AEs) were compared between the two groups. Factors affecting survival were identified <i>via</i> Cox regression analysis.<h4>Results</h4>Compared with the TACE group, the combination group had a highe"],"journal":["Frontiers in oncology"],"pagination":["874473"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9068979"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study."],"pmcid":["PMC9068979"],"pubmed_authors":["Pan H","Qu S","Zhang J","Wang R","Zhang X","Fang Q","Hu L","Wu D","Meng Y","Wu Y","Wei L"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study.","description":"<h4>Purpose</h4>To compare the efficacy and safety of the combination of transcatheter arterial chemoembolization (TACE), Lenvatinib, and programmed cell death protein-1 (PD-1) inhibitors (combination group) with TACE (TACE group) in the treatment of patients with unresectable hepatocellular carcinoma (uHCC).<h4>Methods</h4>We consecutively enrolled 110 patients with uHCC in this prospective cohort study, with 56 patients receiving combination treatment and 54 patients receiving TACE from November 2017 to September 2020. The differences in tumor response, survival benefit, and adverse events (AEs) were compared between the two groups. Factors affecting survival were identified <i>via</i> Cox regression analysis.<h4>Results</h4>Compared with the TACE group, the combination group had a highe","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-18T14:14:59.785Z","creation":"2025-04-07T00:19:21.764Z"},"accession":"S-EPMC9068979","cross_references":{"pubmed":["35530353"],"doi":["10.3389/fonc.2022.874473"]}}